Acridine carboxamide

Acridine carboxamide
Identifiers
	IUPAC name N-[2-(Dimethylamino)ethyl]-4-acridinecarboxamide;
CAS Number	89459-25-6;
PubChem CID	107805;
ChemSpider	96954;
CompTox Dashboard (EPA)	DTXSID60237739 ;
Chemical and physical data
Formula	C8H19N3O
Molar mass	293.363 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCNC(=O)C1=CC=CC2=CC3=CC=CC=C3N=C21;
	InChI InChI=1S/C18H19N3O/c1-21(2)11-10-19-18(22)15-8-5-7-14-12-13-6-3-4-9-16(13)20-17(14)15/h3-9,12H,10-11H2,1-2H3,(H,19,22); Key:XBGNERSKEKDZDS-UHFFFAOYSA-N;

Acridine carboxamide is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.^[1]^[2]^[3]^[4]

References

^ Dittrich C; Dieras V; Kerbrat P; et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Caponigro F; Dittrich C; Sorensen JB; et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Twelves C; Campone M; Coudert B; et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Dittrich C; Coudert B; Paz-Ares L; et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Dittrich C; Dieras V; Kerbrat P; et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[2] Caponigro F; Dittrich C; Sorensen JB; et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[3] Twelves C; Campone M; Coudert B; et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[4] Dittrich C; Coudert B; Paz-Ares L; et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[1]

[2]

[3]

[4]

See also

References